Infusion of a V2R antagonist, com pared with placebo and AVP, improved survival, mean arterial pressure, and cardiac index as well as metabolic, liver, and renal dysfunction. Along with AVP, selective V2R antagonists and V1a receptor agonists represent promis ing new therapies.